Correspondence to Editorial on the USF1/HKDC1/SMS Axis in Lenvatinib Resistant and Immune Escape in HCC
Clinical and Molecular Hepatology · 05.11.2026
DOI: 10.3350/cmh.2026.0487 ↗Kurz gefasst
Leserbrief in der Zeitschrift Clinical and Molecular Hepatology, online erschienen am 05.11.2026. Verfasst von Shiping Chen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China; Key Laboratory of Carcinogenesis and Cancer Invasion, Fudan Uni….
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China; Key Laboratory of Carcinogenesis and Cancer Invasion, Fudan University, Ministry of Education, Shanghai, 200032, China.
- State Key Laboratory of Genetic Engineering, Fudan University, Shanghai, 200433, China.
- Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China; Key Laboratory of Carcinogenesis and Cancer Invasion, Fudan University, Ministry of Education, Shanghai, 200032, China. dai.zhi@zs-ho…
- State Key Laboratory of Genetic Engineering, Fudan University, Shanghai, 200433, China. dai.zhi@zs-hospital.sh.cn.
Zitieren
APA
Chen, S., & Dai, Z. (2026). Correspondence to Editorial on the USF1/HKDC1/SMS Axis in Lenvatinib Resistant and Immune Escape in HCC. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2026.0487
Vancouver
Chen S, Dai Z. Correspondence to Editorial on the USF1/HKDC1/SMS Axis in Lenvatinib Resistant and Immune Escape in HCC. Clinical and Molecular Hepatology. 2026. doi:10.3350/cmh.2026.0487
BibTeX
@article{Chen2026,
author = {Chen, Shiping and Dai, Zhi},
title = {Correspondence to Editorial on the USF1/HKDC1/SMS Axis in Lenvatinib Resistant and Immune Escape in HCC},
journal = {Clinical and Molecular Hepatology},
year = {2026},
doi = {10.3350/cmh.2026.0487}
}
EUVIMED